TEVA
Income statement / Annual
Last year (2023), Teva Pharmaceutical Industries Limited's total revenue was $15.85 B,
an increase of 6.16% from the previous year.
In 2023, Teva Pharmaceutical Industries Limited's net income was -$559.00 M.
See Teva Pharmaceutical Industries Limited’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$15.85 B
|
$14.93 B
|
$15.88 B
|
$16.66 B
|
$16.89 B
|
$18.85 B
|
$22.39 B
|
$21.90 B
|
$19.65 B
|
$20.27 B
|
| Cost of Revenue |
$8.20 B |
$7.95 B |
$8.28 B |
$8.93 B |
$9.35 B |
$10.56 B |
$11.56 B |
$10.04 B |
$8.30 B |
$9.22 B |
| Gross Profit |
$7.65 B |
$6.97 B |
$7.59 B |
$7.73 B |
$7.54 B |
$8.30 B |
$10.83 B |
$11.86 B |
$11.36 B |
$11.06 B |
| Gross Profit Ratio |
0.48 |
0.47 |
0.48 |
0.46 |
0.45 |
0.44 |
0.48 |
0.54 |
0.58 |
0.55 |
| Research and Development
Expenses |
$953.00 M
|
$838.00 M
|
$967.00 M
|
$997.00 M
|
$1.01 B
|
$1.21 B
|
$1.85 B
|
$2.11 B
|
$1.53 B
|
$1.49 B
|
| General & Administrative
Expenses |
$1.16 B
|
$1.18 B
|
$1.10 B
|
$1.17 B
|
$1.19 B
|
$1.30 B
|
$1.33 B
|
$1.24 B
|
$1.24 B
|
$1.22 B
|
| Selling & Marketing
Expenses |
$2.34 B
|
$2.27 B
|
$2.43 B
|
$2.50 B
|
$2.61 B
|
$2.92 B
|
$3.66 B
|
$3.86 B
|
$3.48 B
|
$3.86 B
|
| Selling, General &
Administrative Expenses |
$3.50 B
|
$3.45 B
|
$3.53 B
|
$3.67 B
|
$3.81 B
|
$4.21 B
|
$4.99 B
|
$5.10 B
|
$4.72 B
|
$5.08 B
|
| Other Expenses |
-$14.00 M |
$107.00 M |
$98.00 M |
-$4.00 M |
$76.00 M |
$291.00 M |
$1.20 B |
$636.00 M |
$23.00 M |
-$17.00 M |
| Operating Expenses |
$4.45 B |
$4.28 B |
$4.50 B |
$4.67 B |
$4.82 B |
$5.43 B |
$6.83 B |
$7.21 B |
$6.24 B |
$6.57 B |
| Cost And Expenses |
$12.65 B |
$12.24 B |
$12.78 B |
$13.60 B |
$14.17 B |
$15.99 B |
$18.39 B |
$17.25 B |
$14.54 B |
$15.78 B |
| Interest Income |
$0.00 |
$920.00 M |
$891.00 M |
$24.00 M |
$41.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.03 B |
$966.00 M |
$1.06 B |
$963.00 M |
$822.00 M |
$959.00 M |
$895.00 M |
$1.33 B |
$1.00 B |
$313.00 M |
| Depreciation &
Amortization |
$1.15 B
|
$1.31 B
|
$1.33 B
|
$1.56 B
|
$1.72 B
|
$1.84 B
|
$2.08 B
|
$1.49 B
|
$1.31 B
|
$1.51 B
|
| EBITDA |
$4.27 B
|
$4.11 B
|
$4.53 B
|
$4.61 B
|
$3.21 B
|
$3.16 B
|
$5.19 B
|
$4.65 B
|
$5.11 B
|
$4.49 B
|
| EBITDA Ratio |
0.27 |
0.28 |
0.29 |
0.28 |
0.19 |
0.17 |
0.23 |
0.21 |
0.26 |
0.22 |
| Operating Income Ratio
|
0.03
|
0.19
|
0.2
|
0.18
|
0.17
|
-0.09
|
-0.78
|
0.1
|
0.17
|
0.19
|
| Total Other
Income/Expenses Net |
-$2.72 B
|
-$5.86 B
|
-$2.54 B
|
-$7.46 B
|
-$4.06 B
|
-$4.51 B
|
-$21.48 B
|
-$2.50 B
|
-$1.76 B
|
-$539.00 M
|
| Income Before Tax |
-$624.00 M |
-$3.07 B |
$658.00 M |
-$4.41 B |
-$1.27 B |
-$2.60 B |
-$18.38 B |
$824.00 M |
$2.35 B |
$3.64 B |
| Income Before Tax Ratio
|
-0.04
|
-0.21
|
0.04
|
-0.26
|
-0.07
|
-0.14
|
-0.82
|
0.04
|
0.12
|
0.18
|
| Income Tax Expense |
-$7.00 M |
-$638.00 M |
$211.00 M |
-$168.00 M |
-$278.00 M |
-$195.00 M |
-$1.93 B |
$521.00 M |
$634.00 M |
$591.00 M |
| Net Income |
-$559.00 M |
-$2.35 B |
$417.00 M |
-$3.99 B |
-$999.00 M |
-$2.15 B |
-$16.27 B |
$329.00 M |
$1.59 B |
$3.06 B |
| Net Income Ratio |
-0.04 |
-0.16 |
0.03 |
-0.24 |
-0.06 |
-0.11 |
-0.73 |
0.02 |
0.08 |
0.15 |
| EPS |
-0.5 |
-2.12 |
0.38 |
-3.64 |
-0.92 |
-2.11 |
-16.01 |
0.07 |
1.84 |
3.58 |
| EPS Diluted |
-0.5 |
-2.12 |
0.38 |
-3.64 |
-0.92 |
-2.11 |
-16.01 |
0.07 |
1.82 |
3.56 |
| Weighted Average Shares
Out |
$1.12 B
|
$1.11 B
|
$1.10 B
|
$1.10 B
|
$1.09 B
|
$1.02 B
|
$1.02 B
|
$955.00 M
|
$855.00 M
|
$853.00 M
|
| Weighted Average Shares
Out Diluted |
$1.12 B
|
$1.11 B
|
$1.11 B
|
$1.10 B
|
$1.09 B
|
$1.02 B
|
$1.02 B
|
$961.00 M
|
$864.00 M
|
$858.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
